Physician profile
Miranda Adanna Ewelukwa
NPI 1174967756
$22,344.65
in general payments reported to CMS, 2019-2025
40 companies · $6,952 in 2025
The $6,952 reported for 2025 was more than what 94% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $960 · 2021: $2,154 · 2022: $3,371 · 2023: $3,277 · 2024: $4,348 · 2025: $6,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,925 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,359.21 |
| Consulting Fee | $1,925.00 |
| Education | $293.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,902.72 | 2019-2025 | |
| Janssen Biotech, INC. | $2,938.48 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $2,824.03 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $1,510.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,379.15 | 2019-2025 | Dupixent |
| Amgen INC. | $1,119.45 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $968.77 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $968.04 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $872.08 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $812.04 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $800.30 | 2020-2025 | |
| Pfizer INC. | $726.93 | 2019-2025 | |
| Galderma Laboratories, L.P. | $621.65 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Sun Pharmaceutical Industries INC. | $585.91 | 2019-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $427.47 | 2019-2024 | Cabtreo, Jublia, Arazlo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Ewelukwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.